Efficacy and safety of inhaled formoterol 4.5 and 9 μg twice daily in Japanese and European COPD patients: Phase III study results

BACKGROUND: This study evaluated the efficacy and safety of the long-acting β(2)-agonist formoterol in patients with moderate-to-severe COPD. METHODS: This double-blind, placebo-controlled, parallel-group, multinational phase III study randomized patients ≥ 40 years of age with moderate-to-severe CO...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Bogdan, Miron A, Aizawa, Hisamichi, Fukuchi, Yoshinosuke, Mishima, Michiaki, Nishimura, Masaharu, Ichinose, Masakazu
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2011
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3233513/
https://ncbi.nlm.nih.gov/pubmed/22085439
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2466-11-51
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller